Curriculum Vitae

DR. LIONG CHEE CHIAT

Medical Lecturer
  • Department of Medicine
    Faculty of Medicine
  • liongcc
  • 0379494422

ACADEMIC QUALIFICATION


  • MBBS, (Medicine and Surgery)
    International Medical University (imu)
  • MIntMed, (Internal Medicine)
    Universiti Malaya (UM)

MEMBERSHIPS


  • MALAYSIAN SOCIETY OF HAEMATOLOGY, MEMBERSHIP
    Since 2019 (National)
  • LIFE MEMBER OF THE MALAYSIAN SOCIETY OF HAEMATOLOGY, MEMBER
    Since 2019 (National)
  • FULL MEMBER OF BRITISH SOCIETY FOR HAEMATOLOGY, MEMBER
    2022 to 2022 (International)
  • MEMBER OF BRITISH SOCIETY OF HAEMATOLOGY, MEMBER
    2021 to 2021 (International)

RESEARCH PROJECT


National
  1. 2024 - 2026, Partnership Grant
    Developing An Online Course On Chronic Myeloid Leukaemia For Postgraduate Medical Students ( Co-Researcher)
  2. 2021 - 2027, MORPHOSYS AG
    A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL COMPARING THE EFFICACY AND SAFETY OF TAFASITAMAB PLUS LENALIDOMIDE IN ADDITION TO R-CHOP VERSUS R-CHOP IN PREVIOUSLY UNTREATED, HIGH-INTERMEDIATE AND HIGH-RISK PATIENTS WITH NEWLY-DIAGNOSED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) ( Co-Researcher)
  3. 2021 - 2025, JOHNSON & JOHNSON SDN. BHD.
    A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE CLINICAL OUTCOMES, ANTIVIRAL ACTIVITY, SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACOKINETICS/PHARMACODYNAMICS OF JNJ-53718678 IN ADULT AND ADOLESCENT HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION OF THE UPPER RESPIRATORY TRACT ( Co-Researcher)
  4. 2022 - 2025, NS PHARMA, INC.
    A PHASE 2B, OPEN-LABEL, MULTICENTER, RANDOMIZED, CONTROLLED, 2-ARM STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORALLY ADMINISTERED NS-018 VERSUS BEST AVAILABLE THERAPY IN SUBJECTS WITH PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS, OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS WITH SEVERE THROMBOCYTOPENIA (PLATELET COUNT ( Co-Researcher)
Private
  1. 2024 - 2033, MERCK SHARP & DOHME LLC
    A PHASE 3, RANDOMIZED STUDY TO COMPARE NEMTABRUTINIB VERSUS COMPARATOR (INVESTIGATOR S CHOICE OF IBRUTINIB OR ACALABRUTINIB) IN PARTICIPANTS WITH UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BELLWAVE-011) ( Co-Researcher)
  2. 2024 - 2029, NORVATIS CORPORATION (M) SDN. BHD.
    AN OPEN-LABEL, MULTICENTER, ROLL-OVER STUDY FOR PATIENTS WHO HAVE COMPLETED A PRIOR NOVARTIS-SPONSORED SABATOLIMAB (MBG453) STUDY AND ARE JUDGED BY THE INVESTIGATOR TO BENEFIT FROM CONTINUED TREATMENT WITH SABATOLIMAB ( Co-Researcher)
  3. 2025 - 2028, CELGENE CORPORATION
    A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY COMPARING THE EFFICACY AND SAFETY OF GOLCADOMIDE PLUS R-CHOP CHEMOTHERAPY VS PLACEBO PLUS R-CHOP CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED HIGH-RISK LARGE B-CELL LYMPHOMA (GOLSEEK-1) ( Co-Researcher)
  4. 2023 - 2027, Novartis Corporation (Malaysia) Sdn. Bhd.
    A PHASE IIIB, MULTI-CENTER, OPEN-LABEL, RANDOMIZED STUDY OF TOLERABILITY AND EFFICACY OF ORAL ASCIMINIB VERSUS NILOTINIB IN PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOGENOUS LEUKEMIA IN CHRONIC PHASE ( Co-Researcher)
  5. 2024 - 2027, VIRACTA THERAPEUTICS, INC.
    AN OPEN-LABEL, PHASE 2 TRIAL OF NANATINOSTAT IN COMBINATION WITH VALGANCICLOVIR IN PATIENTS WITH EPSTEIN-BARR VIRUS-POSITIVE (EBV+) RELAPSED/REFRACTORY LYMPHOMAS (NAVAL-1) ( Co-Researcher)
  6. 2023 - 2026, Private Funding
    Developing A Masterclass In Chronic Myeloid Leukaemia ( Co-Researcher)
International
  1. 2022 - 2027, CONSTELLATION PHARMACEUTICAL, INC
    A Phase 3, Randomized, Double-blind, Active-Control Study of Pelabresib (CPI-0610) and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients ( Principal Investigator(PI))
  2. 2026 - 2027, PHAMACOSMOS A/S
    AN OPEN-LABEL, DOSE-ESCALATION, DOSE-FINDING, AND PROOF-OF-CONCEPT TRIAL OF SP-420 IN SUBJECTS WITH TRANSFUSION-DEPENDENT - OR -THALASSEMIA OR LOW-RISK MYELODYSPLASTIC SYNDROMES ( Co-Researcher)
  3. 2023 - 2024, JANSSEN RESEARCH & DEVELOPMENT, LLC
    EFFICACY AND SAFETY OF M281 IN ADULTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY WITH A LONG-TERM OPEN-LABEL EXTENSION ( Co-Researcher)
  4. 2022 - 2023, ASTRAZENECA SDN. BHD.
    A MULTICENTER RETROSPECTIVE STUDY TO UNDERSTAND THE CLINICAL CHARACTERISTICS, TREATMENT PATHWAY AND RESOURCE UTILIZATION FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). ( Co-Researcher)
  5. 2019 - 2022, INTERNATIONAL MYELOMA FOUNDATION
    Randomized Phase 3 study of Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) versus Pomalidomide-Dexamethasone (PD) in relapse or refractory myeloma. An AMN study ( Co-Researcher)
University
  1. 2025 - 2027, Bantuan Khas Penyelidikan (BKP Special)
    Investigating the Impact of Genetic Polymorphisms on Renal Failure in Patients Receiving High-Dose Methotrexate Therapy: A Clinical Approach ( Co-Researcher)

PAPER PRESENTED


PLENARY SPEAKER
  1. A Journey into the World of Chronic Myeloid Leukaemia, Live Webinar Series: BREAKFAST@UMHEALTH, Faculty of Medicine, Universiti Malaya (University) (21 Sep 2022 - 21 Oct 2022)
INVITED SPEAKER
  1. Challenges in Managing Patients with Fungal Infection, Molecular & Non-molecular Diagnostic Of Invasive Fungal Infections, Faculty of Medicine, Univesiti Malaya (National) (13 Sep 2022 - 14 Sep 2022)
  2. Understanding Blood Cancers, BENGKEL LIVING WITH BLOOD CANCER 2022, Haematology Unit, Faculty of Medicine, Universiti Malaya (National) (09 Aug 2022 - 09 Aug 2022)
POSTER PRESENTER
  1. PREVALENCE OF INVASIVE FUNGAL INFECTION IN PATIENTS WITH ACUTE LEUKAEMIA IN A TEACHING HOSPITAL, Malaysian Society of Haematology Scientific Meeting 2022, Malaysia Society of Haematolgoy (National) (09 Aug 2022 - 11 Oct 2022)